Abstract
Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Current Stem Cell Research & Therapy
Title:Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Volume: 13 Issue: 5
Author(s): Feng Li, Tengfei Zhang, Ling Cao and Yi Zhang*
Affiliation:
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan,China
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Abstract: Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Export Options
About this article
Cite this article as:
Li Feng , Zhang Tengfei , Cao Ling and Zhang Yi *, Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180420110239
DOI https://dx.doi.org/10.2174/1574888X13666180420110239 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Current Medicinal Chemistry Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Liver Cancer Stem Cells as an Important Target in Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Long-Term Immunovirogical Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice
Current HIV Research Synthesis and Antiproliferative Evaluation of Spirothiadiazolopyridazine Derivatives
Letters in Drug Design & Discovery The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism